PhaseV uses causal machine learning and generative AI to optimize clinical trial designs and improve drug development processes.
Subscribe to see PhaseV’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
PhaseV is a biotech company headquartered in Israel, founded in 2023. It has raised at least $65M across the 2 funding rounds on record. Its most recent funding round, Series A, raised $50M in May 2025. Xcout tracks 3 named people at PhaseV, including Raviv Pryluk, PhD (CEO, Co-Founder). Xcout recorded 17 job postings from PhaseV in the last 90 days.
At least $65M raised across the 2 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series A | $50M | 2 named | |
| — | $15M | 2 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Xcout recorded 17 job postings from PhaseV in the last 90 days, from a hiring record Xcout has kept since June 2026.
The weekly hiring trend, the roles and locations behind it — see PhaseV's hiring signals →
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Post the link and the card appears automatically — each network fetches the image itself.